Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Post-preeclampsia Renal Project: Study of Nephroprotection in Women Having Suffered Preeclampsia (RPPEC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by University Hospital, Geneva
Information provided by (Responsible Party):
Antoinette Pechere-Bertschi, MD, University Hospital, Geneva Identifier:
First received: March 29, 2010
Last updated: May 10, 2016
Last verified: May 2016
The purpose of the Post-preeclampsia Renal Project is to investigate the renal function of preeclamptic women after delivery, and to determine whether the anti-hypertensive drug named benazepril efficiently improves the dysfunctions observed.

Condition Intervention Phase
Renal Alteration
Drug: Placebo
Drug: Benazepril hydrochloride
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Benazepril (ATC N° C09AA07) in the Treatment of Persistent Renal Dysfunction in Pre-eclamptic Women

Resource links provided by NLM:

Further study details as provided by University Hospital, Geneva:

Primary Outcome Measures:
  • microalbuminuria excretion rate (spot or 24h) [ Time Frame: Baseline; 1 week + 24 weeks after treatment start ]
  • eGFR [ Time Frame: Baseline; 1 week + 24 weeks after treatment start ]

Secondary Outcome Measures:
  • Filtration fraction % [ Time Frame: Baseline; 1 week + 24 weeks after treatment start ]
  • 24h Ambulatory Blood Pressure [ Time Frame: Baseline; 1 week and 24 weeks after treatment start ]
    Mean; diurnal; nocturnal

  • Effective Renal Plasma Flow [ Time Frame: Baseline; 1 week and 48 weeks after treatment start ]
  • Adverse Events [ Time Frame: From signature of informed consent until last follow-up visit (36 months after treatment start) ]

Estimated Enrollment: 120
Study Start Date: April 2010
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Control Arm Drug: Placebo
Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
Experimental: Benazepril Drug: Benazepril hydrochloride
Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
Other Names:
  • Cibacen
  • Lotensin
  • ATC: C09AA07

Detailed Description:

Several epidemiological studies suggest that the risk of death from cardiovascular causes among women with preeclampsia may be increased, and that preeclampsia contrary to what has been long thought, is not cured with delivery. Preeclampsia has long been considered a 2-stage disease, stage one corresponding to an impaired placental perfusion resulting from abnormal spiral artery remodeling, and stage two corresponding to the maternal manifestations of disease, characterized by hypertension and proteinuria. However, preeclampsia might include an additional, 3rd stage, that of the post-partum period (Gammill & Roberts, 2007) This phase deserves to be investigated. In particular, it is crucial to determine whether the changes that occur in renal hemodynamics during preeclampsia are reversible after more than 6 weeks, and whether PEC women are salt-sensitive after delivery.

The link between chronic kidney disease and cardiovascular mortality is well established. An independent, graded association exists between a reduced GFR and the risk of death, cardiovascular events, and hospitalization (Go et al, 2004). Besides, salt-sensitivity is associated with an increased cardiovascular and renal risk (Franco & Oparil, 2006). The Renal Post PEC study aims at establishing if the renal dysfunctions that occur in PEC women can be reversed by the administration of inhibitors of the renin-angiotensin system that are known to improve cardiovascular and renal risk profiles in hypertensive patients. By virtue of their potent renal vasodilatory properties and favourable remodelling of the GBM, ACE inhibitors may improve salt-sensitivity, endothelial function, renal plasma flow and GFR, and general renal prognosis in women who experienced from preeclampsia.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Pre-selection Criteria:

  • Normotensive women with no proteinuria before the 20th week of gestation AND
  • Women with hypertension (BP ≥140/90 mm Hg) and proteinuria (≥ 0.3 g /24h or 2++ dipstick) after the 20th week of gestation

Inclusion Criteria:

  • Clearance of creatinine ≤ 80 ml/min (Gault et Cockcroft)
  • Serum creatinine ≥ 80 µmol/L
  • Microalbuminuria comprised between 30 and 300 mg/d and/or a urinary spot with microalbuminuria/creatinine ratio ≥ 3.5 and/or macroalbuminuria (24h urinary albumin excretion ≥ 0.500 mg)
  • BP ≥ 140/90 mm Hg OR ongoing antihypertensive treatment
  • CRP ≥ 4 mg/dL

Exclusion Criteria:

  • Those unlikely to co-operate in the study
  • Those who refuse to use appropriate contraceptive measures during the treatment period (intrauterine device, oral contraceptives, condom, diaphragm)
  • Those with a history of pre-term delivery
  • Those with known history of severe allergic reaction
  • Those who consume drugs
  • Aged < 18 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01095939

Contact: Antoinette Pechère, MD +41223729598
Contact: Jocelyne Chabert, PhD +4179 55 32 217

Geneva University Hospitals Recruiting
Geneva, Switzerland
Contact: Antoinette Pechère, MD    +41 22 372 95 98   
Principal Investigator: Antoinette Pechère, MD         
Centre Hospitalier Universitaire Vaudois Recruiting
Lausanne, Switzerland
Contact: Michel Burnier, MD    +41 21 692 50 08   
Contact: Gregoire Wuerzner    +41 21 314 11 14   
Principal Investigator: Michel Burnier, MD         
Sponsors and Collaborators
University Hospital, Geneva
Principal Investigator: Antoinette Pechère University Hospital, Geneva
  More Information

Responsible Party: Antoinette Pechere-Bertschi, MD, Dr, University Hospital, Geneva Identifier: NCT01095939     History of Changes
Other Study ID Numbers: 09-136
Study First Received: March 29, 2010
Last Updated: May 10, 2016

Keywords provided by University Hospital, Geneva:
Renal function consecutive to pre-eclampsia

Additional relevant MeSH terms:
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents processed this record on April 28, 2017